- Global Pharma News & Resources

Neurological Biomarkers Market to achieve CAGR of 11.6% from 2023 and 2032, owing to increasing prevalence of neurological diseases | insightSLICE

The global Neurological Biomarkers market size was estimated to be US$ 6.9 billion in 2021 and is expected grow at a CAGR of 11.6% between 2023 to 2032.

In the report on the Neurological Biomarkers Market, we discuss the trends and analyses of the global market with a prediction for 2022–2032. In addition to taking into account the competitive climate, the forecast study will contain a summary of the key players in the worldwide in vitro fertilization (IVF) market along with their market projections.

The report would also cover notable developments, regional and global sales subsidiaries, corporate strategies, R&D projects, staff size, and chief employees for all leading market participants.

Access the sample report:

According to the company’s product segment analysis Laboratory Products & Services section, accounted for the majority of Thermo Fisher Scientific Inc.’s US$ 24.4 billion in revenue in 2018.

The key players of the Global Neurological Biomarkers Market are:

Alseres Pharmaceuticals Inc., Abbott Laboratories, Acumen Pharmaceuticals Inc., AbaStar MDx Inc., Athena Diagnostics, Bio-Rad Laboratories Inc., BANYAN BIOMARKERS, INC., QIAGEN, Myriad RBM Inc., and Thermo Fisher Scientific Inc. are significant market participants in the global neurological biomarkers market.

What are the recent development and growth impacts for this market?

The market for neurological biomarkers is expanding significantly on a global scale. The principal growth factors include increasing expenditure, the incidence of neurological illnesses, and increased awareness.

The blood and extremely minute amounts of cerebral spinal fluid (CSF) both contain neurological biomarkers. Because of this, it is challenging to find and recognize the natural biomarkers that are found in the blood. Without invasive surgery, the neurological biomarkers in the cerebral spinal fluid (CSF) cannot be accessed.

However, technological advancements have made it possible to track biomarker clusters or signatures in blood cells. This has helped the market for neurological biomarkers expand. Neurological biomarkers are also becoming more widely accepted globally since they make early detection and tracking of neurological illnesses possible.

Read more about the report inclusions:

What is covered in our report for neurological biomarkers market?

The report will discover major companies involved in the neurological biomarker market, with various products and technology used. This report gives an in-depth analysis of key companies holding the bulk of the global market share across all operating business segments.

It will also cover market shares of well-known firms present in the global neurological biomarker market. To quote an example from the report, Thermo Fisher Scientific Inc. has four divisions called Life Sciences Solutions, Laboratory Products & Services, Specialty Diagnostics, and Analytical Instruments.

Their Life Sciences Solutions division provides neurological biomarkers tools and services and accounted for a revenue contribution of US$ 6.1 billion in 2018.

The report includes the analysis of crucial competitive data from all the neurological biomarker firms, such as corporate strategy, market position, SWOT analysis, key developments, and market specialization.

The analysis of the worldwide market for neurological biomarkers will also consider the competitors and their contributions to the market ecosystem. All of the items in the company’s neurological biomarkers corporate sector will be the central objective of the product line segment.

Comparable to this, the section on significant innovations would concentrate on the firm’s most recent research activities along with strategic alliances and collaborations, mergers and acquisitions, and new product development.

Regional performance of Neurological Biomarkers Market

Due to its emphasis on neurological screening testing and therapies, North America accounted for the biggest share of the global market for neurological biomarkers in 2019.

The main causes of the increased need for neurological biomarkers in North America include the frequency and development of neurological diseases in the United States as well as raising awareness.

China, India, and other Asia-Pacific nations, as well as Japan, are making major investments in the study of new treatments and clinical medicine for neurological disorders. During the forecast timeframe, the market for neurological biomarkers in Asia-Pacific is expected to be among the most lucrative.

Related reports:

Global Medical Thermometer Market:

Global Medical Oxygen Concentrators Market:

Global Neurological Biomarkers Market Key Segments:

By Type

  • Genomic
  • Proteomic
  • Metabolomic
  • Imaging
  • Others

By Application

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorder
  • Others

By End Use

  • Hospital & Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Research Organizations and Others

By Geography:

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 28-Nov-2022